Litigation settlements, net (1,984) (46,154)
Integration and other non-
recurring expenses (3) 56,142 -
Tax effect of the above items (57,412) 18,761
Adjusted net earnings available to
common shareholders and adjusted
diluted cash EPS $238,265 $0.92 $253,732 $1.18
(1) The three months ended December 31, 2007 include amortization expense
related to purchased intangible assets as well as amortization of the
inventory step-up related to Merck Generics. The nine months ended
December 31, 2007 include amortization expense related to purchased
intangible assets and amortization of the inventory step-up related to
both Merck Generics and Matrix.
(2) The three and nine months ended December 31, 2007 include the premium
related to a tender offer made to holders of the Company's previously
outstanding Senior Notes, the write-off of deferred finance fees and
non-recurring financing fees and expenses related to the Company's
previously outstanding Interim Term Loan.
(3) The three and nine months ended December 31, 2007 principally include
non-recurring expenses related to the acquisition and integration of
Merck Generics (e.g., non-recurring professional and consulting fees,
retention and other non-recurring expenses).
This press release includes statements that constitute "forward-looking
statements", including with regard to the Company's future growth
expectations, its strategic initiatives including with regard to its Dey
business and Matrix's Docpharma business, the Company's synergy targets,
the impact of the Perforomist(TM) launch on future EPS expectations, its
planned rationalizations and optimizations of its businesses, a
|SOURCE Mylan Inc.|
Copyright©2008 PR Newswire.
All rights reserved